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Summary
There is an urgent need to provide effective anti-HIV microbicides to resource-poor areas
worldwide. Some of the most promising microbicide candidates are biotherapeutics targeting
viral entry. To provide biotherapeutics to poorer areas, it is vital to reduce the cost. Here, we
report the production of biologically active recombinant cyanovirin-N (rCV-N), an antiviral
protein, in genetically engineered soya bean seeds. Pure, biologically active rCV-N was isolated
with a yield of 350 lg/g of dry seed weight. The observed amino acid sequence of rCV-N
matched the expected sequence of native CV-N, as did the mass of rCV-N (11 009 Da). Purified
rCV-N from soya is active in anti-HIV assays with an EC50 of 0.82–2.7 nM (compared to 0.45–
1.8 nM for E. coli-produced CV-N). Standard industrial processing of soya bean seeds to harvest
soya bean oil does not diminish the antiviral activity of recovered rCV-N, allowing the use of
industrial soya bean processing to generate both soya bean oil and a recombinant protein for
anti-HIV microbicide development.
Introduction
The HIV/AIDS pandemic is one of the largest global health
concerns, with over 35 million people worldwide living with HIV
and women in developing countries account for more than half of
new infections (UNAIDS, 2013). Prevention strategies such as
topical microbicides that can be used by women are urgently
needed. Currently, no microbicides for HIV are on the market,
and most candidates in late-stage development are formulated
with antiretroviral (ARV) drugs that inhibit viral replication (Friend
and Kiser, 2013). The potential for viral resistance to ARVs,
however, presents a strong challenge to their long-term use as
microbicides, as such resistance could adversely affect current
therapeutic options. It is therefore imperative to identify novel
non-ARV microbicide agents to prevent HIV infection.
Cyanovirin-N (CV-N), an 11 009 Da protein isolated from
cultures of the cyanobacterium Nostoc ellipsosporum, is a potent
lectin capable of irreversibly inactivating diverse strains of HIV
(types 1 and 2) and simian immunodeficiency virus (Boyd et al.,
1997). CV-N also prevents virus-to-cell fusion, virus entry and
infection of cells in vitro (Tsai et al., 2003). These properties
appear to be mediated through conserved interactions of CV-N
with the viral surface envelope glycoprotein gp120 that are
distinct from the interactions of gp120 with the cellular receptor
CD4 or with antibodies to known HIV-neutralizing determinants
of gp120 (Boyd et al., 1997).
The antiviral efficacy of CV-N is coupled with its environmental
stability (active over broad pH ranges, organic solvents and
temperatures nearing boiling point) and stability in macaque
cervical vaginal lavage fluid (Tsai et al., 2003). Recombinant CV-N
(rCV-N) has been produced in Escherichia coli and is analogous to
a natural CV-N (Mori et al., 1998). The efficacy of gel-formulated
rCV-N was evaluated in macaques rectally and vaginally chal-
lenged against SHIV86.9P: results demonstrated that rCV-N as a
topical microbicide gel can prevent transmission of SHIV in
macaques (Tsai et al., 2003, 2004). This result has encouraged
further preclinical evaluation of CV-N to prevent sexual transmis-
sion of HIV in humans (Brichacek et al., 2013; Buffa et al., 2009;
Lagenaur et al., 2011; Li et al., 2011; Xiong et al., 2010).
Although bioactive rCV-N can be produced in a bacterial
expression system, it is currently considered a nonviable option
for large-scale production due to the higher intrinsic cost.
Researchers have therefore tried to produce rCV-N in other
expression systems such as Pichia pastoris (Mori et al., 2002),
Nicotiana tabacum (Elghabi et al., 2011; Sexton et al., 2006) and
Althaea officinalis (Drake et al., 2013) with the aim of finding the
most efficient production system. These candidate expression
systems for the practical application of rCV-N to HIV microbicide
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development are still limited by their lack of a scalable and
economically viable platform to produce bioactive rCV-N (O’Keefe
et al., 2009). Although such a platform exists to recombinantly
produce the microbicidal agent griffithsin (GFRT) in Nicotiana
benthamiana leaves using a viral-vector-based system (O’Keefe
et al., 2009), there are no reports on current capacity to produce
rCV-N using a similar approach.
Soya bean protein storage vacuoles (PSVs) are temporal
organelles of the endoplasmic reticulum specialized in accumu-
lating and storing seed proteins (Kim and Krishnan, 2004; Mori
et al., 2009; Robinson et al., 2005; Takaiwa et al., 2007). The a’-
subunit of the b-conglycinin promoter and signal peptide is
efficient tissue-specific regulatory sequences that control accu-
mulation of b-conglycinin, the most abundant seed storage
protein in soya bean (Imoto et al., 2008; Ladin et al., 1987;
Wilson et al., 1986; Yamada et al., 2008). These seed-specific
regulatory sequences were successfully used to demonstrate the
efficacy of accumulating different proteins in soya bean seeds
(Cunha et al., 2011a,b; Kim and Krishnan, 2004; Yamada et al.,
2008). Here, we report that rCV-N accumulates to a level of at
least 350 mg of protein per kilogram of dry seed when the cv-n
gene is directed to protein storage vacuoles of soya bean seeds
via biolistics (Cunha et al., 2011a,b; Rech et al., 2008).
Based on our results on high soya bean seed production and
the capacity to produce 350 lg of pure rCV-N per gram of dry
seed, we estimated that at least 1 kg of pure rCV-N can be
produced in a 1524 square metre area of enclosed greenhouse
space. We demonstrate that rCV-N produced in soya bean seeds
has potent nanomolar anti-HIV activity against T-tropic laboratory
strains of HIV-1, which is comparable to the activity range of
native CV-N and also displays a concentration-dependent binding
to the viral envelope glycoprotein gp120. Furthermore, we also
show that soya bean seeds expressing rCV-N can be processed
using the already available soya bean industrial processing system
to produce high-quality raw material ready to enter the purifi-
cation system as well as soya bean oil indistinguishable from that
produced by control soya bean seeds.
Results
Production of rCV-N in soya bean seeds
Expression of rCV-N was achieved using specific regulatory
sequences within soya bean seed tissues. A co-bombardment
transformation strategy to generate transgenic soya bean plants
allowed us to evaluate the pbcongCVN plasmid vector (Figure 1).
The cv-n gene encoding 101 amino acids cloned under control of
the a’-subunit of the b-conglycinin seed-specific promoter and
35S terminator was effective in directing CV-N protein to the
PSVs. The selection plasmid carried the herbicide-resistant ahas
gene (under control of the ahas constitutive promoter and
terminator) and allowed for the selection of putative transfor-
mants on imazapyr, as previously described (Rech et al., 2008).
Transgenic soya bean lines were generated following the micro-
particle co-bombardment system as previously described (Rech
et al., 2008). After co-bombardment of 10 independent exper-
iments, each with 250 embryonic axes, eight putative transgenic
plants containing both cv-n and ahas genes were obtained. All 8
plants demonstrated biosynthesis of the mature rCV-N with the
expected molecular weight of approximately 11 kDa. Soya bean
line CV-N10 presented the highest expression as determined by
ELISA analysis of T1 progeny and was used to advance derived
progenies and for all further experiments.
Organ-specific detection and expression kinetics of the
recombinant CV-N
The expression of rCV-N in different organs of a T3 transgenic
soya bean plant line was evaluated by Western blot. As expected,
rCV-N was only detected in protein extracts from seeds,
demonstrating that the a’-subunit of the b-conglycinin tissue-
specific promoter was efficient in restricting the gene expression
to only the soya bean cotyledons. No rCV-N was detected in
roots, leaves, stems or flowers of the transgenic plant, or in
nontransgenic seeds (Figure 2a). The kinetics of the CV-N protein
accumulation during seed development was evaluated 2, 4, 6 and
8 weeks after pollination (Figure 2b): rCV-N protein accumula-
tion increased during seed development. Northern blot analyses
indicated there were no detectable transcripts of rCV-N at
2 weeks after pollination, but we observed an increased accu-
mulation from 4 to 8 weeks (Figure 2c). Western blot analysis
revealed that the accumulation of the rCV-N increased during the
development cycle of the seeds, reaching its highest level in the
mature seeds 8 weeks after pollination (Figure 2d).
Localization of rCV-N in transgenic soya bean seeds
Ultrastructural immunocytochemistry analysis using gold particle
visualization showed the accumulation of the rCV-N in the PSVs
of mature seeds (Figure 3, gold particles are seen as dark spots
denoted by arrows). Detectable rCV-N was localized within the
PSVs of transgenic soya bean seeds with no significant accumu-
lation inside the oil bodies or in the cell wall (Figure 3a, b) and nor
was gold particle accumulation found in the apoplast, starch
grains or cytoplasm of transgenic seeds. Nontransgenic seed did
not present detectable accumulation of rCV-N in the PSVs
(Figure 3c).
Figure 1 Schematic representation of the expression cassettes of the pbCong1CV-N and pAC321 plasmids used for particle bombardment transformation
of soya bean embryos. The Cyanovirin-N (cv-n) gene is under the control of the a’-subunit of b-conglycinin promoter and signal peptide, and also the
CaMV35S terminator. In the pAC321 plasmid, the ahas gene is controlled by the ahas promoter and terminator (t-ahas).
ª 2015 Society for Experimental Biology, Association of Applied Biologists and John Wiley & Sons Ltd, Plant Biotechnology Journal, 1–9
Barry R. O’Keefe et al.2
Purification and analysis of rCV-N from soya bean seeds
Pure, biologically active rCV-N was isolated from lyophilized soya
bean seed powder with a yield of 350 lg/g of dry seed weight by
a combination of aqueous extraction, ethanolic precipitation and
C-18 reverse-phase chromatography. Pure rCV-N was obtained
from the ethanolic precipitate. The soluble fraction following
ethanolic precipitation (67% EtOH) also contained rCV-N; how-
ever, purification proved more difficult as other contaminating
proteins co-purified with rCV-N in almost all fractions. We
therefore focused on optimizing purification of rCV-N from the
insoluble fraction. Figure 4(a) shows the Coomassie-stained SDS-
PAGE analysis of selected fractions during the purification
procedure, and purified rCV-N (lane 6, Figure 4a) migrated in a
similar way to the positive control CV-N (lane 1, Figure 4a).
Western blot analysis showed that the purified rCV-N (lane 2,
Figure 4b) was antigenically similar to the positive control (lane 3,
Figure 4b, rCV-N from E. coli), and both were detected as
monomers when blots were probed with rabbit anti-CV-N
antibodies. Other forms of rCV-N were detected in the soluble
fraction as expected (lane 1, Figure 4b); however, these were
separated from the active monomer by the reverse-phase
purification protocol. The purified rCV-N was confirmed to be a
monomer of 11 010 Da [M+] by LC-MS analysis (Figure S1),
which is consistent with the expected size of 11 009 Da for
native CV-N. The observed N-terminal amino acid sequence of
rCV-N also matched exactly with the expected N-terminal
sequence of native cyanovirin (data not shown). Finally, amino
acid analysis showed that rCV-N exhibited 92% purity when
compared against the expected composition for native CV-N.
Bioactivity of purified rCV-N
Anti-HIV activity analysis of the purified rCV-N shows it is potently
active in a concentration-dependent manner at protecting against
HIV-1RF-induced cytopathic effects in CEM-SS cells with an EC50
of 0.82–2.7 nM (8–30 ng/mL) compared to 0.45–1.8 nM (5–
20 mg/mL) for E. coli-produced CV-N tested simultaneously
(Figure 5). These results compare favourably to the anti-HIV
activity originally reported for native CV-N (approximately 1 nM)
(Boyd et al., 1997). The purified rCV-N did not show cytotoxicity
at the highest concentration tested (1 lg/mL, 90 nM) (Figure 5)
which is >30-fold higher than its EC50. Both rCV-N and E. coli-
produced CV-N were also tested against HIV-1IIIB resulting in
similar EC50 values of 0.82 and 0.36 nM, respectively (data not
shown). The rCV-N was further tested for its ability to bind HIV
envelope glycoprotein gp120 in an ELISA, and results show that
like the control CV-N sample, rCV-N bound gp120 in a concen-
tration-dependent manner with essentially identical affinity
(Figure 6).
Stability of rCV-N after soya bean downstream
processing
Soya bean seeds producing rCV-N protein were tested for the
presence of rCV-N in oil extracted from T3 transgenic soya bean
seeds. No rCV-N was detected in the oil fraction, but a stable
fraction of rCV-N was detected in protein extracts processed for
oil removal (Figure S2). A comparison of the fatty acid content in
control versus rCV-N transgenic soya bean seeds showed no
significant differences in either the yield or composition of soya
bean oil produced (Table S1).
Discussion
Development of a suitable expression source for the manufacture
of an anti-HIV topical microbicide requires a low cost method-
ology to have the broadest utility in areas of the world most
affected by HIV (Essex, 1996; Gartner et al., 1986; O’Keefe et al.,
2009). Suitable microbicide candidates must meet an array of
criteria including potency; broad-spectrum activity against differ-
ent HIV strains; selectivity for viral and/or host cell targets;
prevention of cell-to-cell transmission; stability both in transit and
in vivo; bioavailability in target mucosa; and low toxicity to
mucosal surfaces, including direct irritation, immunogenicity and
mitogenicity (Essex, 1996; Gartner et al., 1986). Despite the
availability of potential microbicides meeting some of these
functional criteria, few have been able to be produced at
(a)
(b)
(c)
(d)
(e)
(f)
Figure 2 The efficiency of the a’-subunit of b-conglycinin promoter to
restrict the transgene expression to the transgenic seeds was evaluated by
organ-specific Western blot analysis. (a) Immunoassays of TSP extracts
(100 lg) from roots, stems, flowers and seeds of a transgenic a T3 plant
from transgenic line CV-N10 and a nontransgenic plant demonstrated the
successful detection of rCV-N only in transgenic seeds. A total of 100 ng
of rCV-N purified from E. coli (NIH) was properly detected by primary
antibody recognition. All molecular weights were estimated with the
marker Precision Plus Protein Standards All Blue (Bio-Rad). (b) The kinetics
expression of the cv-n gene on the transcriptional and translational levels
was demonstrated in different phenological stages of T3 soya bean seeds
from line CV-N10. Samples were evaluated after 2, 4, 6 and 8 weeks after
pollination. (c) Northern blot detection of primary transcripts of the cv-n
gene 4 weeks after pollination, showing an increase after 8 weeks
(above). Ubiquitous elongation factor gene transcripts were detected
showing homogeneous mRNAs concentration in all stages of seed
development (below). (d) Western blot analysis of transgenic seeds
showing the accumulation of the rCV-N in seeds from 2 to 8 weeks after
pollination, with an increase in the last stages of development (above).
SDS-PAGE loading controls of each total soluble protein extracts
(approximately 100 lg) were utilized to provide a uniform sample
electrophoresis (below).
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sufficiently low cost. One exception is the recent report of the use
of a TMV-based expression system based on agroinfiltration of
Nicotiana benthamiana leaves that demonstrated the capacity to
produce rGRFT-P (O’Keefe et al., 2009) on a scale sufficient to
support clinical development.
Here, we report that engineering soya bean seeds to express
the anti-HIV protein CV-N allowed us to develop a scalable
(c)
(a)
(b)
Figure 3 Protein targeting to protein storage vacuoles (PSV) was
evaluated by ultrastructural immunocytochemistry of the rCV-N presence
in sections (2 mm) of soya bean cotyledons. (a, b) Subcellular
accumulation of the rCV-N in the PSV of transgenic T3 seeds from line
CV-N10. The accumulation of rCV-N was restricted to the PSVs (white
arrows), with no significant detection of the protein associated to the oil
bodies (OB) and the cell wall (CW). (c) The rCV-N could not be detected in
the PSVs of nontransgenic seeds, as shown in the experimental control.
(a) (b)
Figure 4 Analysis of the rCV-N purification process. (a) Coomassie Blue-
stained SDS-PAGE (reducing conditions) of fractions from the purification
procedure. Lanes marked as 1: pure, active CV-N produced in E. coli
(positive control), 2: SeeBlue Plus2 (Invitrogen) molecular weight standard,
3: total soluble protein, 4: supernatant from 67% ethanol precipitation, 5:
resuspended pellet from 50% ethanol precipitation and 6: pure rCV-N
isolated in fraction 38 from reverse phase-HPLC. (b) Western blot
(reducing conditions) for detection of CV-N in selected fractions from the
purification. Lanes marked as 1: total soluble protein, 2: pure rCV-N
isolated in fraction 38 from reverse phase-HPLC, 3: pure CV-N produced in
E. coli (positive control) and 4: SeeBlue Plus2 (Invitrogen) molecular weight
standard.
Figure 5 Concentration-dependent anti-HIV activity of soya-produced
rCV-N in HIV-1RF infected (●) and uninfected (○) CEM-SS cells assessed
after 6 days in culture. The activity of control CV-N, produced in E. coli,
was also tested on infected (▼) and uninfected (M) CEM-SS cells. The
number of surviving cells was measured by the XTT method and is
indicated as percent untreated uninfected cell control. The assay was
repeated several times, and soya-produced rCV-N displayed EC50 values in
the range of 0.82-2.7 nM, while E. coli-produced CV-N showed EC50
values in the range of 0.45-1.8 nM. Both samples showed no toxicity at
the highest tested dose (approximately 90 nM)
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platform to produce biologically active rCV-N protein, which
provides an important alternative for the production of bioactive
proteins including microbicides. The cv-n gene cloned under
control of the b-conglycinin seed-specific regulatory sequences
was effective in directing rCV-N to PSVs in soya bean seeds.
Moreover, this strategy was efficient in producing the monomer,
11 kDa rCV-N protein. These results are in accordance with
previous studies demonstrating that seed-specific regulatory
sequences can be successfully used to express stably accumulated
molecules with different structural characteristics, in the PSVs of
transgenic soya bean seeds (Cunha et al., 2011a,b; Kim and
Krishnan, 2004; Yamada et al., 2008).
We also demonstrate that the kinetic accumulation pattern of
rCV-N during the maturation cycle of soya bean seeds was
temporally modulated. Its peak was reached approximately
4 weeks after pollination and maintained steadily until the dry
seed maturation stage. These results are in agreement with our
previous findings expressing human growth hormone (Cunha
et al., 2011a) and human coagulation factor (Cunha et al.,
2011b) in soya bean seed, which could be correlated with the
kinetics pattern of the PSV organelles’ availability (Yoo and
Chrispeels, 1980). Localization of rCV-N in the seeds was
indicated by ultrastructural immunocytochemistry analysis. The
a’-subunit of the b-conglycinin promoter and signal peptide was
effective in directing rCV-N protein accumulation in mature soya
bean seeds. The accumulation profile indicated that rCV-N
protein was restricted to the PSVs, and absent in the apoplast
and oil bodies. Our results are in agreement with previous
findings (Hohl et al., 1996; Muntz, 1998; Vitale and Raikhel,
1999).
We successfully purified rCV-N from the insoluble fraction of
transgenic soya bean seeds by several ethanolic precipitation
steps followed by a final separation with reverse-phase chroma-
tography. We obtained a calculated yield of 350 lg/g of dry seed
weight with 92% purity. The predominant contaminants were
low molecular weight. However, they can be easily removed by
an additional gel filtration step. The soluble fraction and other
nonpure fractions of the final purification step also contained
bioactive rCV-N; however, these often contained other contam-
inating proteins. This indicates a higher yield of purified rCV-N is
possible, and future work will focus on optimizing purification
conditions to increase the total yield of pure rCV-N.
Once purified, the rCV-N was characterized as a monomer of
11 009 Da, with its N-terminal sequence identical to native CV-N.
Though denatured during purification, rCV-N refolded correctly
after reverse-phase HPLC, as confirmed by its potent anti-HIV
activity and binding to gp120, which closely correlate to that of
native CV-N (Boyd et al., 1997). Active at low nanomolar
concentrations against HIV-1RF and HIV-1IIB, the rCV-N was active
in the same range as CV-N produced in E. coli (Boyd et al., 1997)
and tested simultaneously. The facile refolding of rCV-N is similar
to that previously reported (Boyd et al., 1997; Mori et al., 1998)
and speaks to the physiochemical stability of this protein, an
important advantage for both production and shipping.
As a potential scalable and low-cost platform for production of
rCV-N, transgenic soya bean may constitute one of the least
expensive systems for its large-scale production. Under green-
house conditions, the soya bean plant has a high biomass
capacity and it is photoperiod-sensitive, which means that
increasing the length of the light period will induce a delay in
flowering and, consequently, high vegetative growth (Cavazzoni
et al., 1999; Kantolic and Slafer, 2007). This photoperiod
sensitivity, together with the intrinsically high protein content
(40%) in the seeds makes soya bean an attractive system for the
production of recombinant proteins. Soya bean is a short-day
plant, and its developmental responses are regulated by phyto-
chrome photoreceptors (Watanabe et al., 2009; Wu et al.,
2013). Under field and greenhouse conditions, each soya bean
plant under a 10-14 h photoperiod produces on average 100
seeds in its progeny. An increase in the photoperiod to 23–24 h
induces a strong vegetative growth of the plant. After a period of
3 months of vegetative growth, the readjustment of photoperiod
to 10–14 h induces flowering and large-scale seed production.
This procedure allows production of more than 1000 seeds per
plant. Based on our results on soya bean seed production (1000
seeds per plant) and the capacity to produce 350 lg of pure rCV-
N per gram of dry seed, it is possible to estimate the production of
at least 1 Kg of pure rCV-N in an area of 1524 square metres of
enclosed greenhouses. Previous results on the production of
rGRFT microbicide, using a Nicotiana benthamiana-based viral
expression system (O’Keefe et al., 2009) demonstrated a higher
protein expression level of 1 g rGRFT per kg in leaf material and
further production of 60 g of pure rGRFT in 1524 square metres.
Using a soya bean seed-based expression system is estimated to
produce 15 times as much rCV-N in the same area.
Another significant aspect of this research is the viability of
multiple use components from this production stream. The PSVs
of soya bean seeds are an attractive option for the production of
recombinant proteins because simple plasmid construction and
protein engineering allow for the targeting and accumulation of
recombinant proteins in seed storage compartments, which are
separate from the oil storage compartments. Using standard
downstream processes to generate raw soya bean material ready
to go through both oil extraction and rCV-N purification, this
method is rapidly scalable. Furthermore, due to the inherent
physical stability of CV-N (Boyd et al., 1997), soya bean oil could
be extracted from seed material while retaining bioactive rCV-N
in the resulting lyophilized soya powder. We observed that a
stable fraction of recombinant CV-N could be detected in protein
extracts that were processed for oil removal (Figure S2), indicating
that transgenic soya bean seeds can be processed under a
standard industrial manufacturing protocol while retaining prop-
erly folded rCV-N. In addition, the oil produced from the
transgenic seeds was found to be both free of rCV-N (Figure
Figure 6 ELISA study of concentration-dependent binding of pure, active
rCV-N from E. coli (▲) and soya bean seeds (●) to HIV envelope
glycoprotein gp120. Points are averages of triplicate samples (corrected
for the blocking agent background values).
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S2) and of similar fatty acid composition to oil extracted from
control seeds (Table S1). This dual use of the soya bean, both for
microbicide production and for soya bean oil production, provides
further cost savings for this expression system. Though the scale
at which CV-N would be produced will not result in the scale of
production normally used for oil extraction efforts such as
biodiesel production, the oil recovered from rCV-N processing
could find additional uses as a secondary product as lecithins (e.g.
printing inks, insecticides, synthetic rubbers) or glycerols
(cements, structured lipids, lubricants) for industrial purposes
(Dashiell, 1989).
A current priority in anti-HIV microbicide development is the
identification and validation of non-ARV compounds that would
prevent cross-over resistance to clinical agents used therapeuti-
cally against HIV. Candidate non-ARV anti-HIV microbicides must
meet stringent requirements such as safety, efficacy and afford-
ability metrics (Shattock and Rosenberg, 2012). Though previous
experiments in cell culture have indicated some potential adverse
effects associated with CV-N treatment (Kouokam et al., 2011),
studies in nonhuman primate models have not shown similar
deleterious effects (Brichacek et al., 2013). CV-N has also been
repeatedly shown to be effective in both vaginal and rectal
challenge models of SHIV in macaques (Lagenaur et al., 2011; Li
et al., 2011; Tsai et al., 2003, 2004). One of the difficulties in
fully evaluating CV-N as a microbicide has been the high cost of
production. CV-N produced in soya bean seeds addresses this
critical requirement, and soya beans should be further evaluated
as a production system to produce other suitable candidate
microbicides for further preclinical evaluation and possibly, clinical
testing in humans.
Experimental procedures
Vector construction
The 306-bp fragment corresponding to cv-n gene coding region
(GenBank accession number: L48551.1) was amplified from the
vector pET30b-CVN by polymerase chain reaction (PCR). The
resulting 318-bp sequence was cloned into the sites HindIII and
EcoRI, from the vector pbcong1 (Cunha et al., 2011a,b), which
contains the a’-subunit from b-conglycinin promoter and signal
peptide to generate the vector pbCong1CVN (Figure 1). The
pAC321 selective vector contains the mutated acetohydroxy acid
synthase (ahas) gene, which confers tolerance to the herbicide
imazapyr (Arag~ao et al., 2000).
Producing genetically engineered soya bean plants
Vectors pbCong1CVN and pAC321 were co-bombarded (ratio
1 : 1) into somatic embryonic axes from mature soya bean seeds
of cultivar BR16 (EMBRAPA, Brazil), as previously described (Rech
et al., 2008). Putative transgenic plantlets were kept in a
greenhouse to set seeds.
Preliminary identification of putative transgenic soya
bean plants
For testing ahas and cv-n gene presence, DNA from putative T0
plants was isolated from leaf discs (Doyle and Doyle, 1987), and
PCR analyses were conducted as previously described (Cunha
et al., 2011a,b; Rech et al., 2008). PCR analyses of seed-derived
progeny T1, considered each seed an individual event. A small
piece (1–2 mm2) from the cotyledon was removed, without
damaging the embryos, allowing the isolation of genomic DNA
and further germination of the putative transgenic events.
Northern blot analysis
Transgenic T3 seeds harvested 2, 4, 6 and 8 weeks after
pollination were analysed for the presence of CV-N primary
transcripts. Total RNA from each immature seed (200 mg) was
isolated using a total RNA Purification System (Invitrogen, Life
Technologies, Grand Island, NY) according to the manufacturer’s
protocol. Genomic DNA was eliminated by sample digestion with
2 U of DNase 1 (Ambion, Life Technologies, Grand Island, NY)
for 10 min at 37 °C. Two 32P-labelled probes (at 106 c.p.m./mL)
were used to detect primary transcripts of the cv-n gene and the
internal control corresponding to the endogenous elongation
factor gene. Both probes, with 318 and 560 bp, respectively,
were obtained by PCR as previously outlined (Li et al., 2006).
Autoradiograms were obtained by exposing the membranes to
BioMax MS film (Kodak, Rochester, NY).
Localization of rCV-N in soya bean seeds
For the ultrastructural immunocytochemistry analysis of rCV-N in
cotyledons of transgenic plant lines, mature T3 transgenic seeds
were used and the analyses were conducted as previously
described (Cunha et al., 2011a,b).
Quantification of rCV-N in soya bean transgenic seeds
(ELISA)
Total soluble protein (TSP) extracts from soya bean leaves, stems,
flowers, roots and seeds (each seed weighed approximately
200 mg) were obtained by homogenizing 1.5 g of each organ in
10 mL PBS buffer (10 mM Na2HPO4, 1.7 mM NaH2PO4, 140 mM
NaCl, 2.7 mM KCl, pH 7.2). Samples were homogenized on ice
with three 30s pulses on the lowest setting of a Polytron PT
(Kinematica, Bohemia, NY) and immediately frozen at 80 °C.
Samples were thawed on ice and centrifuged at 12 000 g for
10 min at 4 °C, and the aqueous supernatant was collected. The
supernatant was filtered with a Millipore 0.22-lm polyethersulf-
one disc filter under sterile conditions. Protein concentrations
were determined using Pierce BCA Protein Assay Reagent
(Quantum Scientific, VWR Inc., West Chester, PA) following
manufacturer’s instructions. ELISA was performed to determine
the rCV-N concentration in the TSP extracts from T1 seeds as
described in ELISA section below. Seeds presenting higher
expression levels were chosen for further cultivation in green-
house.
Extraction and purification of rCV-N
Lyophilized soya bean seeds were crushed to a fine powder (8 g)
and extracted with 100 mL extraction buffer (50 mM PBS,
0.02% NaN3, 1 : 100 dilution of protease inhibitor cocktail,
Sigma-Aldrich) at 4 °C for 120 h, before being filtered (20–
25 lm Whatman filter paper). The insoluble fraction was
resuspended in 50 mL distilled, deionized water (ddH2O) and
centrifuged (16 000 g, 1 h at 4 °C). The pellet was lyophilized,
resuspended in 100 mL ddH2O and precipitated with 67%
ethanol (20 °C overnight) before centrifugation (9000 g, 1 h,
4 °C). The supernatant was concentrated to 5 mL, lyophilized
and reconstituted in ddH2O before being precipitated with 50%
ethanol and centrifuged as before. The resulting pellet was
resuspended in 1 mL ddH2O and separated by reverse phase-
HPLC (Microsorb C-18 column, 5 lm, 10 mm 9 250 mm,
Rainin Instrument Co., Columbus, OH) with a linear gradient
of 0–100% acetonitrile with 0.5% trifluoroacetic acid (TFA) for
60 min at 1.5 mL/min. Collected fractions were dried, resus-
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pended in ddH20 and analysed. Pure rCV-N eluted at 60%–64%
acetonitrile.
SDS-PAGE and Western blot analysis
Samples were resolved on precast NuPAGE 4%–10% Bis-Tris
polyacrylamide gels in MES SDS running buffer (Life Technolo-
gies, Grand Island, NY) under reducing conditions according to
the manufacturer’s instructions. Proteins were visualized by
Coomassie Blue staining or transferred to 0.2 lm PVDF mem-
brane (Invitrogen, Grand Island, NY) for standard Western
blotting: primary antibody was polyclonal rabbit anti-CV-N
antibodies (Molecular Targets Laboratory, CCR, NCI, NIH,
Bethesda, MD) used at 1 : 1500 dilution (overnight incubation),
and secondary antibody was peroxidase-conjugated goat anti-
rabbit antibody (Thermo Fisher Scientific Inc.) used at 1:2000 for
1 h. Western blot was detected using the SignalFire ECL reagent
system (Cell Signaling Technology Inc., Boston, MA).
ELISA studies of the binding of rCV-N to the HIV
envelope glycoprotein gp120
Recombinant HIV-1IIIB gp120 (100 ng/well, ImmunoDiagnostics,
Woburn, MA) coated on a 96-well plate, was blocked with 3%
nonfat dry milk (Bio-Rad) for 2 h and washed thrice with PBST
before being incubated with serial dilutions of rCV-N or control
CV-N (produced in E. coli) for 2 h. Wells were washed with PBST,
incubated for 1 h with a 1:1000 dilution of polyclonal rabbit anti-
CV-N antibody (NIH) and washed as before. Wells were incubated
with peroxidase-conjugated goat anti-rabbit secondary antibody
(Thermo Fisher Scientific Inc., Rockville, MD) at a 1 : 1000
dilution for 1 h. After washing, detection was carried out with
the TMB 2-component Microwell peroxidase substrate kit (KPL
Inc., Gaithersburg, MD) according to the manufacturer’s proto-
col, and absorbance was read at 450 nm.
N-Terminal protein sequencing, amino acid analysis and
mass spectrometry
N-terminal amino acid sequencing and amino acid analysis were
performed (on an Applied Biosystems 494 sequencer (sequential
Edman degradation) and a Beckman 6300 automated amino acid
analyser, respectively. LC-MS was performed on an Agilent 1100
system (Zorbax 300SB-C18 column, 5 lm, 4.6 mm 9 150 mm,
Agilent Technologies, Santa Clara, CA) with a linear gradient of
0–100% acetonitrile with 5% (v/v) acetic acid in the mobile
phase. Corresponding peaks were analysed by electrospray
ionization mass spectrometry.
Anti-HIV activity assays
To assess the anti-HIV activity of rCV-N samples, a 2,3-bis-[2-
methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide
inner salt (XTT)-tetrazolium-based assay was used to determine
the ability of rCV-N to protect the T-lymphoblastic cell line CEM-
SS from a T-tropic laboratory-adapted strain of HIV (HIV-1RF) as
described previously (Gulakowski et al., 1991; Mori et al., 1998).
Additional anti-HIV studies in CEM-SS cell using the same
methodology with both HIV-1RF and HIV-1IIIB were performed at
ImQuest BioSciences LLC. (Frederick, MD).
Soya bean seeds microscale downstream processing
A microscale processing of soya bean seeds was conducted
aiming to simulate the downstream process routinely used in
industry on a large scale. Thirty seeds were processed to separate
oil and protein fractions, and analytical procedures to determine
oil levels and ureatic activity were conducted as previously
described (AOCS, 1998; Erickson, 1995). The analysis was carried
out following good laboratory practices (ITAL/NBR ISO/IEC
17025:2005).
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Figure S1 LC-MS (electrospray ionization) spectrum and decon-
voluted ion set for the purified rCV-N showing the expected
molecular weight of 11 009 Da.
Figure S2 Dot-blot of oil and protein extracts from non-
transgenic and transgenic T3 seeds submitted to standard defat
processing.
Table S1 GC-MS of fatty acids produced by soybean seeds
(NEGC) and soybean seeds producing CV-N (CV-N).
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